The technology is accessible to any laboratory equipped for molecular biology and bacteria culture.
Scientists George P Smith and Gregory Winter were recently awarded half of the 2018 Nobel Prize for Chemistry for developing a technology to display exogenous peptides and proteins on the surface of bacteriophage. 'Phage display' has revolutionised the development of monoclonal antibodies, allowing fully human-derived antibodies to be isolated from large antibody libraries. It has been used for the discovery of many blockbuster drugs, including Humira (adalimumab), the highest selling drug yearly since 2012, with US$18.4b in sales globally in 2017 1 . Phage display can be used to isolate antibodies to almost any antigen for a wide range of applications including clinical use (for cancer, inflammatory conditions and infectious diseases), diagnostic use or as research tools.
The technology is accessible to any laboratory equipped for molecular biology and bacteria culture.
Displaying exogenous peptides and proteins on bacteriophage 4, 5 .
This now allowed the isolation of fully human antibodies, from cloned human antibody gene repertoires, reducing the impact of immunogenicity of mouse-derived therapeutic antibodies.
The bacteriophage biology that allows the display of peptides and proteins is well reviewed by Russel et al. The process of isolating specific antibodies from a phage antibody library is termed 'biopanning', and is summarised in Figure 2 .
Biopanning involves incubating the library of phage particles with immobilised antigen, washing away non-binding phage, and then eluting the bound phage using a buffer that breaks the antibodyantigen interaction. After enriching the library for binding phage, individual clones can be isolated, characterised and further developed as either laboratory tools, or as commercial diagnostic and therapeutic antibodies.
Therapeutic antibodies isolated by phage display
were isolated using phage display [9] [10] [11] [12] (Table 1 ). The majority of therapeutic antibodies target endogenous antigens such as proteins involved in the inflammatory response, or cell-surface or circulating proteins overexpressed in cancers.
Phage-derived antibodies against infectious agents
Therapeutic antibodies can also target infectious agents, including bacteria and viruses; examples include bezlotoxumab, which targets the B toxin of Clostridium difficile, obiltoxaximab and raxibacumab, which target the anthrax toxin, and palivizumab, which targets the F protein of respiratory syncytial virus. These are currently the only antibodies approved for therapy against infectious agents, and only raxibacumab was isolated using phage display. The others were isolated from mice using traditional hybridoma technology followed by humanisation, or using transgenic mice with humanised immune repertoires.
However, phage display, using immunised human antibody librar- and Light chain (blue)), assembled as a single chain variable fragment (scFv), cloned in frame with the gene for the bacteriophage p3 coat protein (green). Right: A bacteriophage particle containing a phagemid vector inside the particle, and the scFv antibody fragment displayed on its surface as a fusion to the p3 protein.
and Rabies virus 18 . Neutralising antibodies can also be isolated from naïve human libraries using phage display. Biopanning strategies for isolation of antibodies to microbial targets requires a source of antigen for incubation with the phage library. The antigen can be a highly purified preparation of the target, for example viral proteins [22] [23] [24] or purified bacterial toxins 25, 26 , or crude preparations such as whole bacterial cells 27, 28 or virus particles 29, 30 .
Advantages of phage display
Phage display offers several advantages over mouse immunisation strategies for antibody discovery, especially for targets that are either toxic or non-immunogenic in a mouse host, or where precision over epitope targeting is required 31 . Guidance towards particular epitopes can be incorporated into the biopanning strategy, by competing with a ligand, or alternating between mouse and human equivalent antigens, or depleting the library to binders that are cross-reactive to similar antigens. For example, antibodies specific for each of the four serotypes of Dengue virus (DENV) NS1 were isolated from a human naïve phage library 32 . Serotype specificity was achieved by first exposing the library to the other three DENV NS1 serotypes to deplete cross-reactive binders.
Such antibodies may be useful in serotyping assays.
Phage display is a simple but powerful tool for antibody discovery, either for therapeutic use or for research tools. It is accessible to any laboratory equipped for standard culturing and molecular biology.
Libraries can be created in-house, obtained commercially (Source Bioscience, Creative Biolabs) or shared from other researchers through material transfer agreements. Within Australia, the National Biologics Facility (NBF) at the University of Queensland offers phage display services and access to their naïve human library, and 
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